211 related articles for article (PubMed ID: 35500152)
1. Super enhancer-LncRNA SENCR promoted cisplatin resistance and growth of NSCLC through upregulating FLI1.
Shen Q; Zhou H; Zhang M; Wu R; Wang L; Wang Y; Chen J
J Clin Lab Anal; 2022 Jun; 36(6):e24460. PubMed ID: 35500152
[TBL] [Abstract][Full Text] [Related]
2. Upregulation of Long Noncoding RNA (lncRNA) X-Inactive Specific Transcript (XIST) is Associated with Cisplatin Resistance in Non-Small Cell Lung Cancer (NSCLC) by Downregulating MicroRNA-144-3p.
Tian LJ; Wu YP; Wang D; Zhou ZH; Xue SB; Zhang DY; Wei YG; Liu W
Med Sci Monit; 2019 Oct; 25():8095-8104. PubMed ID: 31659146
[TBL] [Abstract][Full Text] [Related]
3. LncRNA NNT-AS1 is a major mediator of cisplatin chemoresistance in non-small cell lung cancer through MAPK/Slug pathway.
Cai Y; Dong ZY; Wang JY
Eur Rev Med Pharmacol Sci; 2018 Aug; 22(15):4879-4887. PubMed ID: 30070323
[TBL] [Abstract][Full Text] [Related]
4. Effect of lncRNA-BLACAT1 on drug resistance of non-small cell lung cancer cells in DDP chemotherapy by regulating cyclin D1 expression.
Ju ZS; Sun B; Bao D; Zhang XF
Eur Rev Med Pharmacol Sci; 2020 Sep; 24(18):9465-9472. PubMed ID: 33015788
[TBL] [Abstract][Full Text] [Related]
5. lncRNA RP11-838N2.3 Promoted Cisplatin Resistance in Lung Adenocarcinoma.
Chen J; Jiang F; Hu L; Zhang F; Wang J; Huang K; Wang Y
Biomed Res Int; 2020; 2020():2806042. PubMed ID: 32626737
[TBL] [Abstract][Full Text] [Related]
6. NORAD accelerates chemo-resistance of non-small-cell lung cancer via targeting at miR-129-1-3p/SOX4 axis.
Huang Q; Xing S; Peng A; Yu Z
Biosci Rep; 2020 Jan; 40(1):. PubMed ID: 31894841
[TBL] [Abstract][Full Text] [Related]
7. Circular RNA hsa_circ_0096157 contributes to cisplatin resistance by proliferation, cell cycle progression, and suppressing apoptosis of non-small-cell lung carcinoma cells.
Lu H; Xie X; Wang K; Chen Q; Cai S; Liu D; Luo J; Kong J
Mol Cell Biochem; 2020 Dec; 475(1-2):63-77. PubMed ID: 32767026
[TBL] [Abstract][Full Text] [Related]
8. LncRNA SNHG14 regulates the DDP-resistance of non-small cell lung cancer cell through miR-133a/HOXB13 pathway.
Xu L; Xu Y; Yang M; Li J; Xu F; Chen BL
BMC Pulm Med; 2020 Oct; 20(1):266. PubMed ID: 33059643
[TBL] [Abstract][Full Text] [Related]
9. Long non‑coding RNA AK001796 contributes to cisplatin resistance of non‑small cell lung cancer.
Liu B; Pan CF; Ma T; Wang J; Yao GL; Wei K; Chen YJ
Mol Med Rep; 2017 Oct; 16(4):4107-4112. PubMed ID: 29067469
[TBL] [Abstract][Full Text] [Related]
10. LncRNA SNHG12 in extracellular vesicles derived from carcinoma-associated fibroblasts promotes cisplatin resistance in non-small cell lung cancer cells.
Tan D; Li G; Zhang P; Peng C; He B
Bioengineered; 2022 Jan; 13(1):1838-1857. PubMed ID: 35014944
[TBL] [Abstract][Full Text] [Related]
11. mir-126-5p Promotes Cisplatin Sensitivity of Non-Small-Cell Lung Cancer by Inhibiting ADAM9.
Liu B; Wang R; Liu H
Biomed Res Int; 2021; 2021():6622342. PubMed ID: 34055989
[TBL] [Abstract][Full Text] [Related]
12. LncRNA RP3-326I13.1 promotes cisplatin resistance in lung adenocarcinoma by binding to HSP90B and upregulating MMP13.
Zhou H; Huang X; Shi W; Xu S; Chen J; Huang K; Wang Y
Cell Cycle; 2022 Jul; 21(13):1391-1405. PubMed ID: 35298351
[TBL] [Abstract][Full Text] [Related]
13. Long noncoding LUCAT1 promotes cisplatin resistance of non-small cell lung cancer by promoting IGF-2.
Wang W; Dong ML; Zhang W; Liu T
Eur Rev Med Pharmacol Sci; 2019 Jun; 23(12):5229-5234. PubMed ID: 31298373
[TBL] [Abstract][Full Text] [Related]
14. Hsa_circ_0096157 silencing suppresses autophagy and reduces cisplatin resistance in non-small cell lung cancer by weakening the Nrf2/ARE signaling pathway.
Lu H; Kong J; Cai S; Huang H; Luo J; Liu L
Mol Biol Rep; 2024 Jun; 51(1):703. PubMed ID: 38822881
[TBL] [Abstract][Full Text] [Related]
15. Silence of lncRNA UCA1 rescues drug resistance of cisplatin to non-small-cell lung cancer cells.
Liu X; Huang Z; Qian W; Zhang Q; Sun J
J Cell Biochem; 2019 Jun; 120(6):9243-9249. PubMed ID: 30652341
[TBL] [Abstract][Full Text] [Related]
16. SNHG7 mediates cisplatin-resistance in non-small cell lung cancer by activating PI3K/AKT pathway.
Chen K; Abuduwufuer A; Zhang H; Luo L; Suotesiyali M; Zou Y
Eur Rev Med Pharmacol Sci; 2019 Aug; 23(16):6935-6943. PubMed ID: 31486493
[TBL] [Abstract][Full Text] [Related]
17. LncRNA NORAD/miR-202-5p regulates the drug resistance of A549/DDP to cisplatin by targeting P-gp.
Shen JG; Xu SN; Yin LG
Gen Physiol Biophys; 2020 Sep; 39(5):481-489. PubMed ID: 33084601
[TBL] [Abstract][Full Text] [Related]
18. Knockdown of lncRNA ANRIL inhibits the development of cisplatin resistance by upregulating miR‑98 in lung cancer cells.
Wang X; Zhang G; Cheng Z; Dai L; Jia L; Jing X; Wang H; Zhang R; Liu M; Jiang T; Yang Y; Yang M
Oncol Rep; 2020 Sep; 44(3):1025-1036. PubMed ID: 32705261
[TBL] [Abstract][Full Text] [Related]
19. Downregulated long non-coding RNA TRPM2-AS inhibits cisplatin resistance of non-small cell lung cancer cells via activation of p53- p66shc pathway.
Ma LY; Xie XW; Ma L; Pang JL; Xiong XM; Zheng HD; Shen XL; Wen ZG; Wang HY
Eur Rev Med Pharmacol Sci; 2017 Jun; 21(11):2626-2634. PubMed ID: 28678322
[TBL] [Abstract][Full Text] [Related]
20. Analysis of lncRNA UCA1-related downstream pathways and molecules of cisplatin resistance in lung adenocarcinoma.
Zhou H; Shen Q; Fu J; Jiang F; Wang L; Wang Y
J Clin Lab Anal; 2020 Aug; 34(8):e23312. PubMed ID: 32249461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
